{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:02:08Z","timestamp":1784941328504,"version":"3.55.0"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AstraZeneca","award":["Finanzielle Unterst\u00fctzung d. Manuskripterstellung"],"award-info":[{"award-number":["Finanzielle Unterst\u00fctzung d. Manuskripterstellung"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Im Juli 2025 wurde in Deutschland die perioperative Therapie mit Durvalumab in Kombination mit einer neoadjuvanten Gemcitabin-\/Cisplatin-basierten Chemotherapie und anschlie\u00dfender radikaler Zystektomie zur Behandlung des muskelinvasiven Blasenkarzinoms zugelassen. Die Zulassung basiert auf der Phase-III-Studie NIAGARA, in der gezeigt werden konnte, dass die Kombinationstherapie im Vergleich zur alleinigen neoadjuvanten Chemotherapie zu einer signifikanten Verbesserung des ereignisfreien \u00dcberlebens f\u00fchrte. Zudem war die Rate kompletter pathologischer Remissionen unter Hinzunahme von perioperativem Durvalumab erh\u00f6ht. Dieser Vorteil spiegelte sich auch im Gesamt\u00fcberleben wider, welches unter Kombinationstherapie mit Durvalumab signifikant verl\u00e4ngert war. Dabei wurden weder die Durchf\u00fchrungsrate der Zystektomie beeintr\u00e4chtigt noch deren Komplikationsrate erh\u00f6ht.\n    Ziel dieser Arbeit ist es, das perioperative Therapieregime mit Durvalumab im Kontext der verf\u00fcgbaren Evidenz darzustellen und dessen klinischen Nutzen sowie Limitationen kritisch zu diskutieren. Ein besonderer Fokus liegt auf der Definition geeigneter Kriterien zur Patientenselektion sowie auf der Charakterisierung des Sicherheitsprofils. Dabei werden insbesondere therapieassoziierte schwerwiegende unerw\u00fcnschte Ereignisse der Grade 3\u20134 ber\u00fccksichtigt, wie sie in der NIAGARA-Studie berichtet wurden, darunter An\u00e4mie (14% im Durvalumab-Arm), Neutropenie (14%), Harnwegsinfektionen (14%) sowie eine verminderte Neutrophilenzahl (7%). Der Stellenwert von zirkulierender DNA (ctDNA) als prognostischer Marker wird herausgearbeitet, ohne jedoch die Indikation zur radikalen Zystektomie oder zur adjuvanten Therapie infrage zu stellen. Nicht zuletzt gibt der Artikel einen Ausblick zu neuen perioperativen Therapiekonzepten mit dem Antik\u00f6rper-Wirkstoff-Konjugat Enfortumab Vedotin und Pembrolizumab beim muskelinvasiven Blasenkarzinom.<\/jats:p>","DOI":"10.1055\/a-2883-3946","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:31:39Z","timestamp":1784939499000},"source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Behandlung mit Durvalumab in Kombination mit neoadjuvanter Chemotherapie bei muskelinvasivem Blasenkarzinom und Cisplatin-Eignung"],"prefix":"10.1055","author":[{"given":"Marco Julius","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Caritas-Krankenhaus St. Josef, Lehrstuhl der Universit\u00e4t Regensburg, Germany","place":["Regensburg"],"department":["Klinik f\u00fcr Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Jena, Friedrich-Schiller Universit\u00e4t, Germany","place":["Jena"],"department":["Klinik f\u00fcr Urologie"]},{"name":"Comprehensive Cancer Center Germany (CCCG), Germany","place":["Jena"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[{"name":"Uniklinikum Erlangen, Bavaria, Germany","place":["Erlangen"],"department":["Klinik f\u00fcr Urologie und Kinderurologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-8759","authenticated-orcid":false,"given":"Eva","family":"Hellmis","sequence":"additional","affiliation":[{"name":"Urologicum Duisburg, Germany","place":["Duisburg"],"department":["Praxis Walsum"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Klier","sequence":"additional","affiliation":[{"name":"Urologische Partnerschaft K\u00f6ln, Germany","place":["K\u00f6ln"],"department":["Standort Bayenthal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Germany","place":["Hannover"],"department":["Klinik f\u00fcr H\u00e4matologie, H\u00e4mostaseologie, Onkologie und Stammzelltransplantation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[{"name":"Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Germany","place":["M\u00fcnchen"],"department":["Urologische Klinik und Poliklinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440.","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"M Yin","year":"2016","journal-title":"The Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/jco.2003.05.101.","article-title":"Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy","volume":"21","author":"S Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788.","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"T Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117.","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863.","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"MS van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6.","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"DM Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s1470-2045(10)70275-8.","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"MD Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031.","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"A Dash","year":"2006","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16895.","article-title":"Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy","author":"A Fazili","year":"2025","journal-title":"BJU Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442.","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"DF Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/jco.24.00340.","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"MD Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154.","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/jco.2011.34.8433.","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"MD Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/a-2442-4797.","article-title":"Muscle-invasive and metastatic urothelial carcinoma from a pathological point of view","volume":"56","author":"N Kl\u00fcmper","year":"2025","journal-title":"Aktuelle Urol"},{"issue":"S 05","key":"ref20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1200\/JCO.2025.43.5_suppl.659.","article-title":"Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA","volume":"43","author":"MD Galsky","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"S 16","key":"ref24","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503.","article-title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA","volume":"43","author":"T Powles","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer","volume":"394","author":"C Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"S 07","key":"ref26","doi-asserted-by":"publisher","first-page":"LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630.","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"MD Galsky","year":"2026","journal-title":"Journal of Clinical Oncology"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2883-3946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:31:40Z","timestamp":1784939500000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2883-3946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1055\/a-2883-3946","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}